Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment

CompletedOBSERVATIONAL

Enrollment

812

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

December 12, 2022

Conditions

Non-valvular Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Treatment dose is following the description of physicians.

Trial Locations (1)

Many locations, Multiple Locations